Navigation Links
Nventa Appoints John Varian to Board of Directors
Date:5/7/2008

- New Member Complements Board With Significant Financial and Operational

Expertise -

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation (TSX: NVN) announced today the appointment of John Varian to the company's board of directors. Mr. Varian currently serves as the chief operating officer and chief financial officer of Aryx Therapeutics, a pharmaceutical company focused on the discovery and development of oral therapeutics for chronic disease.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

"We are very pleased to welcome John to Nventa's board," commented Gregory M. McKee, president and chief executive officer at Nventa. "His extensive experience in helping companies establish strategic direction, raise venture and public capital, and negotiate successful alliances and acquisitions should be extremely beneficial to Nventa as it grows internally and continues its path to commercializing its first product."

Prior to joining Aryx Therapeutics, Mr. Varian was chief financial officer of Genset S.A., where he was a key member of the team negotiating the company's sale to Serono S.A. in 2002. From October 1998 to April 2000, Mr. Varian served as senior vice president, finance and administration of Elan Pharmaceuticals, Inc., joining the company as part of its acquisition of Neurex Corporation. Prior to the acquisition, he served as Neurex Corporation's chief financial officer from June 1997 until October 1998. Mr. Varian is a founding member of the Bay Area Bioscience Center and a former chairman of the Association of Bioscience Financial Officers International Conference.

"I am proud to join the board at Nventa Biopharmaceuticals, a truly innovative company that is working to bring much needed therapeutic options to patients affected by HPV-related diseases," stated Mr.
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results
2. Nventa completes enrollment and initial dosing of second cohort in Phase 1 HspE7 safety trial
3. Nventa Biopharmaceuticals Corporation announces third-quarter 2007 financial results
4. Nventa updates progress of cervical dysplasia trial with new HspE7
5. Nventas CEO to present at two upcoming investor conferences
6. Nventa announces publication of HspE7 data
7. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
8. Kendle Appoints Patricia Williams Vice President, Commercial Operations
9. Biomoda Appoints Three Business Leaders to Board of Directors
10. Shengtai Pharmaceutical, Inc. Appoints New CFO
11. Interleukin Genetics Appoints Eliot M. Lurier Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... PHILADELPHIA , Sept. 2, 2014  TransCelerate ... developed a recommended approach for protecting personal data ... with researchers, patients and others. The document describes ... personal information from CSRs and other related clinical ... The goal of the TransCelerate CSR ...
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
(Date:9/2/2014)... 02, 2014 PMG Research, Inc ... clinical research site: PMG Research of Rocky Mount. Effective ... of the clinical research department at Boice-Willis Clinic ... in eastern North Carolina. This new site enhances PMG’s ... in Rocky Mount and the surrounding communities, this brings ...
Breaking Biology Technology:TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3
... Cell Technologies, Inc., a leader in adult stem cell research and ... Stemedica,s Scientific Advisory Board. In this capacity, she will help ... and cellular delivery system for burn and wound management. , ... ...
... the American Society of Clinical Oncology (ASCO) annual meeting, May ... at 5:00 p.m. Eastern Time - REDWOOD CITY, Calif., April ... today announced that the QUASAR validation study met its ... II colon cancer patients following surgery, and that the colon ...
... and CAMBRIDGE, Mass., April 14 ( AACR ... Genstruct Inc. , a systems biology company focused ... develop novel therapeutics, molecular diagnostics and patient-specific therapies, today ... one of its top pharmaceutical partners will be presented ...
Cached Biology Technology:Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 2Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 3Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher 4Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 2Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 3Genomic Health Announces Positive Preliminary Results from QUASAR Validation Study of Oncotype DX(R) Colon Cancer Assay 4Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting 2
(Date:9/2/2014)... of Human Genetics (ASHG) and the National Human ... Institutes of Health, have named Elizabeth P. Tuck, ... School in Columbus, Ohio, the first ASHG/NHGRI Genetics ... , The Genetics and Education Fellowship is intended ... experience, and network to prepare for a career ...
(Date:9/2/2014)... of Evolutionary Biology study provides evidence that ... diversification. , Investigators argue that the same factor ... Galpagos Islands is also responsible for the linguistic ... barriers that impede interaction between speech communities. Therefore, ... due to a reduction of linguistic contact. , ...
(Date:9/2/2014)... sequence their genetic information. How is it possible ... parts of the body are so different? While every ... additional regulatory layer exists that determines which of the ... modifications of genome-bound histone proteins or the DNA itself ... top of the genetic information and is thus called ...
Breaking Biology News(10 mins):ASHG and NHGRI award first genetics and education fellowship 2Throwing a loop to silence gene expression 2
... the momentum of,September,s impressive showing at the ePassports EAC ... ) advances its role as the,world,s ePassport leader by ... to advanced second-generation ePassports based on the,Extended Access Control ... "Second-generation ePassports represent the beginning of an evolution that,will ...
... WALNUT CREEK, Calif. The U.S. Department of Energy Joint ... assembly of the soybean (Glycine max) genetic code, making ... new breeding strategies for one of the world,s most ... 70 percent of the world,s edible protein, but also ...
... as an homage to achievement in the field of coral ... link between corals of the Pacific and Atlantic. Dr. Ann ... McNeill of the University of Miami named a new species ... some six million years old after renowned coral reef ...
Cached Biology News:The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 2The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 3The Finnish Population Register Centre to Deploy Entrust EAC ePassport CA Solution 4DOE Joint Genome Institute completes soybean genome 2DOE Joint Genome Institute completes soybean genome 3Isopora or isn't it? 2
Rat integrin a6b1, mainly associated with epithelial cells. Does not react with rat fibroblasts....
Rabbit polyclonal to Streptococcus Enterotoxin C ( Abpromise for all tested applications)....
Mouse monoclonal [4i144] to HLA Class II DQ1 7 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 2 Antigen DQ1,7....
... 100 g monoclonal antibody which can ... V from heart mitochondria. Also included are ... control immunocapture. The Complex V immunocapture kit ... (E.C. 3.6.3.14) from small amounts of tissue. ...
Biology Products: